Randomised trial comparing the introduction of an immediate or deferred new HAART regimen in failing HIV infected patients: the role of lamivudine monotherapy.

Trial Profile

Randomised trial comparing the introduction of an immediate or deferred new HAART regimen in failing HIV infected patients: the role of lamivudine monotherapy.

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Sep 2012

At a glance

  • Drugs Lamivudine (Primary) ; Abacavir; Antiretrovirals; Atazanavir; Darunavir; Didanosine; Efavirenz; Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate; Emtricitabine; Emtricitabine/tenofovir disoproxil fumarate; Enfuvirtide; Fosamprenavir; Lamivudine/abacavir; Lamivudine/zidovudine; Lopinavir/ritonavir; Maraviroc; Nevirapine; Raltegravir; Ritonavir; Saquinavir; Stavudine; Tenofovir disoproxil fumarate; Tipranavir; Zidovudine
  • Indications HIV infections
  • Focus Therapeutic Use
  • Acronyms MONO
  • Most Recent Events

    • 22 Sep 2012 Status changed from recruiting to completed as reported by European Clinical Trials Database record.
    • 08 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top